Oral Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Intestinal Inflammation
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c07496 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Mona Belaid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Additive Manufacturing Innovation Cluster.
Abstract (Originalsprache)
Despite advances in therapy for inflammatory bowel disease (IBD), current treatments are associated with poor clinical outcomes and systemic side effects. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have therapeutic potential in IBD due to their regenerative and immunomodulatory properties. However, most studies administer MSC-EVs by injection, which does not offer the significant benefits of oral administration, including direct and localized access to the site(s) of intestinal inflammation. Here, we evaluated the stability of MSC-EVs for oral delivery by assessing particle size, concentration, and EV markers. MSC-EVs disintegrated in gastrointestinal (GI) fluids, with cryogenic electron microscopy confirming the loss of structural integrity. To address this, we developed a double-coating formulation consisting of chitosan and Eudragit S100 to enhance GI stability and facilitate colon-targeted delivery. Coated EVs were resistant to GI fluids and digestive enzymes, and the formulation released structurally intact, biologically active vesicles in colonic fluid. Preliminary in vivo studies showed that orally administered coated EVs reduced disease severity in a colitis mouse model and elicited a stronger therapeutic response than uncoated EVs administered orally or intravenously at the same dose. These findings indicate that, with appropriate formulation, oral delivery of MSC-EVs could be an effective route of administration to treat intestinal inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom.
- Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore 117543, Singapore.
- School of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
ORCID-Profile: Mona Belaid, Wei Heng Chng, Ram Pravin Kumar Muthuramalingam, Xiang Luo, Bertrand Czarny
Förderung
- National Additive Manufacturing Innovation Cluster
Zitieren
APA
Belaid, M., Chng, W. H., Muthuramalingam, R. P. K., Lim, Y. W., Javorovic, J., Zhang, Y., Luo, X., Czarny, B., & Vllasaliu, D. (2026). Oral Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Intestinal Inflammation. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c07496
Vancouver
Belaid M, Chng WH, Muthuramalingam RPK, Lim YW, Javorovic J, Zhang Y, et al. Oral Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Intestinal Inflammation. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c07496
BibTeX
@article{Belaid2026,
author = {Belaid, Mona and Chng, Wei Heng and Muthuramalingam, Ram Pravin Kumar and Lim, Yun Wei and Javorovic, Jana and Zhang, Yunyue and Luo, Xiang and Czarny, Bertrand and Vllasaliu, Driton},
title = {Oral Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Intestinal Inflammation},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c07496}
}
EUVIMED